De novo variants in the gene encoding cyclin-dependent kinase 13 (CDK13) have been associated with congenital heart defects and intellectual disability (ID). Here, we present the clinical assessment of 15 individuals and report novel de novo missense variants within the kinase domain of CDK13. Furthermore, we describe 2 nonsense variants and a recurrent frame-shift variant. We demonstrate the synthesis of 2 aberrant CDK13 transcripts in lymphoblastoid cells from an individual with a splice-site variant. Clinical characteristics of the individuals include mild to severe ID, developmental delay, behavioral problems, (neonatal) hypotonia and a variety of facial dysmorphism. Congenital heart defects were present in 2 individuals of the current cohort, but in at least 42% of all known individuals. An overview of all published cases is provided and does not demonstrate an obvious genotype-phenotype correlation, although 2 individuals harboring a stop codons at the end of the kinase domain might have a milder phenotype. Overall, there seems not to be a clinically recognizable facial appearance. The variability in the phenotypes impedes an à vue diagnosis of this syndrome and therefore genome-wide or gene-panel driven genetic testing is needed. Based on this overview, we provide suggestions for clinical work-up and management of this recently described ID syndrome.
| INTRODUCTION
CDK13 (cyclin-dependent kinase 13, OMIM 603309) is a ubiquitously expressed serine/threonine kinase. This kinase uses ATP as a source of phosphate groups and forms, in conjunction with cyclin K, a protein complex which positively regulates transcription through phosphorylation of RNA polymerase II. 1 Furthermore, CDK13 is involved in alternative splicing of RNA, 2, 3 and its mouse homolog regulates axonal elongation. 4 Recently, de novo missense variants located in the kinase domain of CDK13 have been reported. [5] [6] [7] [8] Sifrim et al describe 7 individuals with congenital heart defects, mainly of the ventral and atrial septa. 6 In addition, these individuals showed developmental and motor delay, intellectual disability (ID) and various facial dysmorphisms among other features. A further 6 female individuals with de novo CDK13 variants were reported from the Deciphering Developmental Disorders project. 7 Common phenotypic characteristics of these individuals included ID and dysmorphic facial characteristics. Bostwick et al 5 describe another 9 individuals, showing a similar phenotype with developmental delay (DD)/ID, congenital heart defects, hypotonia and facial dysmorphisms. It is of note that all reported variants in that study are de novo missense variants, with one recurrent variant (p.
Asn842Ser) reported in 7 non-related individuals. Hamilton et al 8 provide extensive clinical information on 16 cases, which included an update on 13 previously reported individuals. 5, 7 In the present study, we performed a clinical evaluation of 15 previously unreported individuals with de novo CDK13 variants. Importantly, in addition to novel missense variants, we describe for the first time nonsense variants in CDK13. This extended cohort, combined with the 25 previously reported individuals, enables us to provide an improved description of the syndromic phenotypic spectrum of individuals with de novo variants in CDK13.
| INDIVIDUALS AND METHODS

| Recruitment and examination of individuals with CDK13 variants
Clinical child-parents whole-exome sequencing (trio-WES) at the 
| mRNA analysis
To study the effects of a splice-site variant in intron 7 of CDK13 in mRNA from Individual 10, lymphoblastoid cell lines were generated from peripheral blood cells by Epstein-Barr virus transformation following standard procedures. 13 To check for the occurrence of nonsense-mediated decay, mRNA was isolated from cells that were cultured in the presence/absence of cyclohexamide. CDK13 mRNA was analyzed by the synthesis of cDNA and Sanger sequencing according to standard protocols.
3 | RESULTS
| Genetic characterization
We identified a broad range of CDK13 variants among the 15 individuals (Table 1 ). In addition to missense variants, nonsense variants and Extensive clinical data are given in Table S1 .
b
Monozygotic twins.
the phosphorylation activity of CDK13. None of the reported CDK13 variants were present in the ExAC/gnomAD databases.
| Phenotypic characterization
The majority of the individuals (9 female, 6 male) were examined at a young age (<14 years), whereas Individuals 5 and 13 were examined at the age of 22 and 54, respectively ( 
| Spectrum of reported variants
In previous publications on individuals with CDK13 variants, only missense (n = 24) variants and 1 splice-site variant were reported 5-8 (Table S3) . Notably, here we describe in addition nonsense and frame-shift variants in CDK13. We could not detect a An overview of all reported individuals is given in Table S3 . (Table S1 and Figure 2 ).
| Mechanistic models
This observation might suggest that there is a similar mode of action between the 2 groups of genetic variants, and a haploinsufficiency model might explain that we could not observe a genotypephenotype correlation. However, currently it is still feasible that 
| Clinical spectrum and suggestions for clinical practice
In Table 1 , we present an overview of the main clinical features of the individuals described in this study and those reported previously. [5] [6] [7] [8] In total 27 female and 13 male individuals are (Table 2 ). Sifrim et al selected for individuals with congenital heart defects (1891 individuals) and identified among their cohort seven individuals with de novo variants in CDK13. 6 All these individuals had septal defects. In the other studies, congenital heart defects were observed as well (over all studies 16/38, 42%), Table 2 ). We suggest echocardiography for individuals with newly discovered will be crucial in diagnosing this new syndrome.
